{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:42:03Z","timestamp":1771004523538,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.ajo.2008.09.010","type":"journal-article","created":{"date-parts":[[2008,10,18]],"date-time":"2008-10-18T04:18:34Z","timestamp":1224303514000},"page":"845-850.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Infliximab Effects Compared to Conventional Therapy in the Management of Retinal Vasculitis in Beh\u00e7et Disease"],"prefix":"10.1016","volume":"146","author":[{"given":"Khalid F.","family":"Tabbara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal I.","family":"Al-Hemidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2008.09.010_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1076\/opep.9.4.239.1507","article-title":"Causes of uveitis at The Eye Center in Saudi Arabia: a retrospective review","volume":"9","author":"Islam","year":"2002","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ajo.2008.09.010_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2008.09.010_bib3","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease; an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajo.2008.09.010_bib4","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","article-title":"Effect of infliximab on threatening panuveitis in Beh\u00e7et's disease","volume":"358","author":"Munoz-Fernandez","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2008.09.010_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2005.12.012","article-title":"Anti-TNF therapies in the management of acute and chronic uveitis","volume":"33","author":"Hale","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.ajo.2008.09.010_bib6","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2008.09.010_bib7","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et's disease","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.ajo.2008.09.010_bib8","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajo.2008.09.010_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et's disease","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.010_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.010_bib11","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ajo.2004.12.009","article-title":"Improving the reporting of clinical case series","volume":"139","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.010_bib12","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1053\/gast.2001.22556","article-title":"Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Beh\u00e7et's disease: a case report","volume":"120","author":"Hassard","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajo.2008.09.010_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et's disease","volume":"26","author":"Abu El-Asrar","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.010_bib14","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.010_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/ard.60.6.637","article-title":"Remission of Beh\u00e7et's syndrome with tumour necrosis factor alpha blocking therapy","volume":"60","author":"Goosens","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajo.2008.09.010_bib16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0161-6420(83)80014-1","article-title":"Chlorambucil in Beh\u00e7et's disease: A reappraisal","volume":"90","author":"Tabbara","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2008.09.010_bib17","first-page":"427","article-title":"The efficacy of single-dose of infliximab in the treatment of Beh\u00e7et's disease uveitis","volume":"23","author":"Arayssi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ajo.2008.09.010_bib18","first-page":"128","article-title":"Systemic levels of the T-cell regulatory cytokines IL-10 and IL-12 in Beh\u00e7et's disease: soluble TNFR-75 as a biological marker of disease activity","volume":"24","author":"Turan","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajo.2008.09.010_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/01.rhu.0000249894.03016.de","article-title":"Beh\u00e7et's disease: recommendation for clinical management of mucocutaneous lesions","volume":"12","author":"Lin","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ajo.2008.09.010_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.20061531","article-title":"Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta","volume":"204","author":"Nadkarni","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.ajo.2008.09.010_bib21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/ard.60.8.750","article-title":"Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNF alpha","volume":"60","author":"Baeten","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajo.2008.09.010_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/ard.2003.008599","article-title":"Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis","volume":"63","author":"Nissinen","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajo.2008.09.010_bib23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/s10165-008-0064-x","article-title":"Decreased percentages of regulatory T cells in peripheral blood of patients with Beh\u00e7et's disease before ocular attack: a possible predictive marker of ocular attack","volume":"18","author":"Nanke","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ajo.2008.09.010_bib24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1196\/annals.1361.095","article-title":"Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab","volume":"1051","author":"Toubi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ajo.2008.09.010_bib25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","article-title":"Anti-TNG-alpha therapy in seven patients with Beh\u00e7et's uveitis: advantages and controversial aspects","volume":"1110","author":"Tognon","year":"2007","journal-title":"Ann N Y Acad Sci"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939408007071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939408007071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:58:00Z","timestamp":1757595480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939408007071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0002939408007071"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2008.09.010","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab Effects Compared to Conventional Therapy in the Management of Retinal Vasculitis in Beh\u00e7et Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2008.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}